Immuno-Oncology Attracts Big Deal Dollars For Biotechs
This article was originally published in Start Up
Executive Summary
Biotechs in the immuno-oncology space can’t operate in a vacuum. To attract funding and partners, their drug candidates must show potential to not only surpass available treatments, but also have the ability to work in tandem with them.